These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10921249)

  • 21. [Treatment of hypertension in renal parenchymal diseases].
    Iversen BM; Kvam FI; Svarstad E
    Tidsskr Nor Laegeforen; 1996 Jun; 116(17):2022-6. PubMed ID: 8766645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antihypertensive therapy in the presence of proteinuria.
    Sarafidis PA; Khosla N; Bakris GL
    Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antihypertensive drugs in renal failure.
    Albert FW
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S108-12. PubMed ID: 7898089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventing renal disease progression: is it the drug or the blood pressure reduction, or both?
    Weir MR
    Curr Hypertens Rep; 2000 Dec; 2(6):497-9. PubMed ID: 11062593
    [No Abstract]   [Full Text] [Related]  

  • 25. [Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].
    Erley CM; Berger ED; Heyne N; Klass M; Krämer D; Braun N; Wolf S; Risler T
    Dtsch Med Wochenschr; 1997 Aug; 122(31-32):953-8. PubMed ID: 9280714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dihydropyridine calcium channel blockers and renal disease.
    Robles NR; Fici F; Grassi G
    Hypertens Res; 2017 Jan; 40(1):21-28. PubMed ID: 27412800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The kidney and strategies for the treatment of hypertension.
    Hollenberg NK
    Am J Med; 1984 Oct; 77(4A):60-3. PubMed ID: 6207726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
    Ritz E; Orth SR; Strzelczyk P
    J Hypertens Suppl; 1997 Mar; 15(2):S21-6. PubMed ID: 9218194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney.
    Thurman JM; Schrier RW
    Am J Med; 2003 May; 114(7):588-98. PubMed ID: 12753883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nephroprotection by antihypertensive agents.
    Schmieder RE
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S55-64. PubMed ID: 7898095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efonidipine improves renal function and decreases proteinuria in elderly hypertensive patients in the JATOS study.
    Okura T
    Hypertens Res; 2010 Nov; 33(11):1112-3. PubMed ID: 20811385
    [No Abstract]   [Full Text] [Related]  

  • 32. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial.
    Minutolo R; Gabbai FB; Borrelli S; Scigliano R; Trucillo P; Baldanza D; Laurino S; Mascia S; Conte G; De Nicola L
    Am J Kidney Dis; 2007 Dec; 50(6):908-17. PubMed ID: 18037091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Proteinuria" itself cannot be taken as a definite marker of improved renal function.
    Chang LC
    Nephrol Dial Transplant; 2010 Nov; 25(11):3799; author reply 3799-800. PubMed ID: 20732923
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapy for hypertension associated with kidney disease].
    Suzuki H
    Nihon Naika Gakkai Zasshi; 2003 Feb; 92(2):264-9. PubMed ID: 12652731
    [No Abstract]   [Full Text] [Related]  

  • 35. Calcium antagonists and the kidney.
    Epstein M
    J Cardiovasc Pharmacol; 1994; 24 Suppl A():S18-24. PubMed ID: 7603073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
    Jovanovic D; Jovovic D; Mihailovic-Stanojevic N; Miloradovic Z; Naumovic R; Dimitrijevic J; Maksic N; Djukanovic L
    Biomed Pharmacother; 2009 Sep; 63(8):571-6. PubMed ID: 19013753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage.
    Perico N; Amuchastegui CS; Malanchini B; Bertani T; Remuzzi G
    Exp Nephrol; 1994; 2(4):220-8. PubMed ID: 8069658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Angiotensin converting enzyme inhibitors in renal diseases].
    Shestakova MV; Kutyrina IM
    Kardiologiia; 2002; 42(9):74-9. PubMed ID: 12494080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease.
    Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1027-37. PubMed ID: 20649501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive treatment and glomerular size selectivity in hypertensive patients with renal parenchymal disease and proteinuria.
    Shand BI; Lewis JG; Elder PA; Agarwal M
    Clin Nephrol; 2002 Oct; 58(4):321-4. PubMed ID: 12400851
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.